A functional variant in the immune signalling receptor NKG2D alters skin cancer risk
Br J Dermatol
.
2022 May;186(5):898-899.
doi: 10.1111/bjd.20943.
Epub 2022 Mar 23.
Authors
Karin A Vineretsky
1
,
Evidio Domingo-Musibay
2
,
Margaret R Karagas
3
,
DeAnn Lazovich
4
5
,
Jacquelyn K Kuriger-Laber
5
,
DeVon Hunter-Schlichting
4
5
,
Heather H Nelson
4
5
Affiliations
1
Department of Environmental Health Sciences, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
2
Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA.
3
Department of Epidemiology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
4
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
5
Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
PMID:
34878657
PMCID:
PMC9064906
DOI:
10.1111/bjd.20943
No abstract available
Publication types
Letter
MeSH terms
Humans
Ligands
NK Cell Lectin-Like Receptor Subfamily K*
Signal Transduction
Skin
Skin Neoplasms*
Substances
Ligands
NK Cell Lectin-Like Receptor Subfamily K
Grants and funding
R01 CA057494/CA/NCI NIH HHS/United States
R01CA82354/CA/NCI NIH HHS/United States
R01 CA106807/CA/NCI NIH HHS/United States
R01CA106807/CA/NCI NIH HHS/United States
R01 CA082354/CA/NCI NIH HHS/United States
R01CA057494/CA/NCI NIH HHS/United States